Osemitamab

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameOsemitamab
Drug Alias NameClaudin18.2 monoclonal antibody - Mabspace BiosciencesClaudin18.2 （CLDN18.2）人源化单克隆抗体（迈博斯）second generation Claudin 18.2 antibody - Transcenta HoldingTST001 - Claudin18.2 monoclonal antibodyTST-001 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-CLDN18
TargetsClaudin-18 splice variant 2
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursLung Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSuzhou Transcenta Therapeutics Co LtdHJB (Hangzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTranscenta Holding LtdSuzhou Transcenta Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursLung Neoplasms +[7] 
Inactive IndicationsEsophageal NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A